Cardiac metabolism in diabetes mellitus

Current Pharmaceutical Design

Volumn 14, Issue 25, 2008, Pages 2521-2526

  Yoshimura, Michihiro ^a,c   Anzawa, Ryuko ^a   Mochizuki, Seibu ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MUSASHINO UNIVERSITY   (Japan)

^c NONE   (Japan)

Author keywords

Cardiomyopathy; Diabetes; Hyperglygemia; Hyperinsulinemia; Metabolism; Renin angiotensin aldosterone system

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCIUM ION; CATECHOLAMINE; CERAMIDE; ELECTROLYTE; FATTY ACID; GLUCOSE; GLUCOSE 6 PHOSPHATE; INSULIN RECEPTOR; ION CHANNEL; METALLOTHIONEIN; MINERALOCORTICOID RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; POTASSIUM ION; PROTEIN KINASE C; PROTON; PYRUVATE DEHYDROGENASE; PYRUVIC ACID; RECEPTOR BLOCKING AGENT; SODIUM ION; SODIUM PROTON EXCHANGE PROTEIN 1; SOMATOMEDIN C; TROGLITAZONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACIDOSIS; ADRENERGIC SYSTEM; ANION EXCHANGE; AUTONOMIC NEUROPATHY; CALCIUM TRANSPORT; CARDIOMEGALY; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISEASE COURSE; DOWN REGULATION; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MICROANGIOPATHY; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPOLARIZATION; REVIEW; SYMPTOMATOLOGY; THERAPY EFFECT; VASODILATATION;

ANIMALS; DIABETES COMPLICATIONS; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC; RENIN-ANGIOTENSIN SYSTEM; SYNDROME;

EID: 57349199292     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786071263     Document Type: Review

References (58)

1. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002; 98: 33-9.
2. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with wellcontrolled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001; 24: 5-10.
3. Valle R, Bagolin E, Canali C, Giovinazzo P, Barro S, Aspromonte N. The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. Eur J Echocardiogr 2006; 7: 40-4.
4. Bell DSH. Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care 1995; 18: 708-14.
5. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 2000; 101: 2271-6
6. Cooper M. Importance of advanced glycation end products in diabetes associated cardiovascular and renal disease. Am J Hypertens 2004; 17: 31S-8S.
7. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-92
8. Nunoda S, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R, et al. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vesse 1985; 1: 43-7
9. Picano E, Pelosi G, Marzilli M, Lattanzi F, Benassi A, Landini L, et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990; 81: 58-64
10. Ungar I, Gilbert M, Siegel A, Blain JM, Bing RJ. Studies on myocardial metabolism: IV. Myocardial metabolism in diabetes. Am J Med 1955; 18: 385-96.
11. Howard BV, Rodriguez BL, Bennett PH, Harris MI, Hamman R, Kuller LH, et al. Prevention Conference VI: diabetes and cardiovascular disease. Writing Group I: epidemiology. Circulation 2002; 105: e132-7.
12. Giles TD, Sander GE. Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations. Cardiol Clin 2004; 22: 553-68.
13. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 3G-10G.
14. Festa A, D'Agostino R Jr, Hales CN, Mykkanen L, Haffner SM. Heart rate in relation to insulin sensitivity and insulin secretion in nondiabetic subjects. Diabetes Care 2000; 23: 624-8.
15. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J 1991; 121: 172-7.
16. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA.. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-94.
17. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I. general concepts. Circulation 2002; 105: 1727-33.
18. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenström A, Wedel H, on behalf of the DIGAMI study group. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J 1996; 17: 1337-44
19. Lou M, Garrett TPJ, McKern NM, Hoyne PA, Epa VC, Bentley J. et al. The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity. Proc Natl Acad Sci 2006; 103: 12429-34.
20. Semsarian C, Wu MJ, Ju YK, Marciniec T, Yeoh T, Allen DG, et al. Skeletal muscle hypertrophy is mediated by a Ca(2+)-dependent calcineurin signalling pathway. Nature 1999; 400: 576-81.
21. Musaro A, McCullagh KJA, Naya FJ, Olson EN, Rosenthal N. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 1999; 400: 581-5.
22. Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2006; 98(5A): 14J-18J. Review.
23. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999; 103: 1489-98.
24. Guerre-Millo M, Rovault C, Poulain P, André J, Poitout V, Peters JM, et al. PPAR-alpha-null mice are protected from high-fat dietinduced insulin resistance. Diabetes 2001; 50: 2809-14.
25. Roduit R, Morin J, Massé F, Segall L, Roche E, Newgard CB, et al. Glucose down-regulates the expression of the peroxisome proliferator-activated receptor alpha gene in the pancreatic beta -cell. J Biol Chem 2000; 275: 35799-806.
26. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II. potential mechanisms. Circulation 2002; 105: 1861-70.
27. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002; 109: 121-30.
28. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97: 1784-9.
29. Singal PK, Belló-Klein A, Farahmand F, Sandhawalia V. Oxidative stress and functional deficit in diabetic cardiomyopathy. Adv Exp Med Biol 2001; 498: 213-20.
30. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 2002; 51: 174-81.
31. + exchanger gene family. J Biol Chem 1992; 267: 9331-9.
32. + exchangers. Physiol Rev 1997; 77: 51-74.
33. Anzawa R, Bernard M, Tamareille S, Baetz D, Confort-Gouny S, Gascard JP, et al. Intracellular sodium increase and susceptibility to ischemia in hearts from type 2 diabetic db/db mice. Diabetologia 2006; 49: 598-606.
34. Anzawa R, Seki S, Horikoshi K, Taniguchi M, Mochizuki S. Exacerbation of acidosis during ischemia and reperfusion arrhythmia in hearts from type 2 Diabetic Otsuka Long-Evans Tokushima Fatty rats. Cardiovasc Diabetol 2007; 6: 17.
35. + exchange: structure, regulation, and its role in heart disease. Circ Res 1999; 85: 777-786.
36. + exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms. Kidney Int 1999; 56: 1400-12.
37. Karmazyn M, Liu Q, Gan XT, Brix BJ, Fliegel L. Aldosterone increases NHE-1 expression and induces NHE-1-dependent hypertrophy in neonatal rat ventricular myocytes. Hypertension 2003; 42: 1171-6.
38. + exchanger and cardiac hypertrophy. Circ Res 1998; 83: 870-3.
39. + exchange prevents hypertrophy, fibrosis, and heart failure in beta1-adrenergic receptor transgenic mice. Circ Res 2002; 90: 814-9.
40. Liu X, Wang J, Takeda N, Binaglia L, Panagia V, Dhalla NS. Changes in cardiac protein kinase C activities and isozymes in streptozotocin-induced diabetes. Am J Physiol 1999; 277: E798-804.
41. Abe T, Ohga Y, Tabayashi N, Kobayashi S, Sakata S, Misawa H, et al. Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am J Physiol Heart Circ Physiol 2002; 282: H138-48.
42. Golfman L, Dixon IM, Takeda N, Lukas A, Dakshinamurti K, Dhalla NS. Cardiac sarcolemmal Na(+)-Ca2+ exchange and Na(+)-K+ ATPase activities and gene expression in alloxan-induced diabetes in rats. Mol Cell Biochem 1998; 188: 91-101.
43. Nakajima T, Iwasawa K, Oonuma H, Imuta H, Hazama H, Asano M, et al. Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes. Circulation 1999; 99: 2942-50.
44. Rozanski GJ, Xu Z. A metabolic mechanism for cardiac K+ channel remodelling. Clin Exp Pharmacol Physiol 2002; 29: 132-7.
45. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998; 41: 39-52.
46. Edwin JK, Garrison JC. Renin and angiotensin. In: Hardman JG, Limbird LE, Molinoff PB, et al. Eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill 1996; 734-58.
47. Scognamiglio R, Casara D, Avogaro A. Myocardial dysfunction and adrenergic innervation in patients with type 1 diabetes mellitus. Diabetes Nutr Metab 2000; 13: 346-9.
48. Saito Y, Nakao K, Nishimura K, Sugawara A, Okumura K, Obata K, et al. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation 1987; 76: 115-24.
49. Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, Kurose M, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide. Circulation 1991; 84: 1581-8.
50. Shono M, Yoshimura M, Nakayama M, Yamamuro M, Abe K, Suzuki S, et al. A predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. Circ J 2007; 71: 1040-6.
51. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
52. Sima A, Popov D, Starodub O, Stancu C, Cristea C, Stern D, et al. Pathobiology of the heart in experimental diabetes: immunolocalization oflipoproteins, immunoglobulin G, and advanced glycation endproducts proteins in diabetic and/or hyperlipidemic hamster. Lab Invest 1997; 77: 3-18.
53. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977; 60: 884-99.
54. Yarom R, Zirkin H, Stämmler G, Rose AG. Human coronary microvessels in diabetes and ischemia. Morphometric study of autopsy material. J Pathol 1992; 166; 265-70.
55. Yoon Y, Uchida S, Masuo O, Cejna M, Park JS, Gwon H, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy. Circulation 2005; 111: 2073-85.
56. Calkin AC, Jandeleit-Dahm KA, Sebekova E, Allen TJ, Mizrahi J, Cooper ME, et al. PPARs and diabetes-associated atherosclerosis. Curr Pharm Des 2007; 13(26): 2736-41.
57. Combettes M, Kargar C. Newly approved and promising antidiabetic agents. Therapie 2007; 62(4): 293-310.
58. Thompson CS. Animal models of diabetes mellitus: relevance to vascular complications. Curr Pharm Des 2008; 14(4): 309-24.